Injectable CBD Liposomes Work Better Than Oral CBD in Dogs With Arthritis

Randomized, blinded, placebo-controlled, crossover trial in 8 client-owned dogs (4M, 4F; median age 8.5 years; median weight 34.9 kg) with radiographically confirmed osteoarthritis. Two subcutaneous injections 4 weeks apart: 7 mg/kg liposomal synthetic CBD (L-sCBD, 50 mg/mL) and empty liposomes (placebo). Blood sampled for CBD and metabolites, CBC, and serum chemistry up to 4 weeks post-injection.

Poor oral bioavailability is the single biggest limitation of current CBD therapeutics—for both animals and humans. If injectable liposomal CBD can provide sustained therapeutic levels from a single injection, it could transform how CBD is used for chronic pain. The veterinary application also matters directly: many dog owners already give their pets oral CBD for arthritis with questionable absorption.

This addresses the same bioavailability problem as RTHC-00179 (DehydraTECH oral formulation) and the nanotechnology approaches reviewed in RTHC-00184—but from a completely different angle: bypassing oral absorption entirely. RTHC-00182's null result for oral CBD in knee osteoarthritis raises the question of whether the negative finding was due to CBD not working for OA or due to insufficient drug reaching the joints. An injectable formulation could help answer that question.

Very small sample (8 dogs). Veterinary data—dog pharmacokinetics and OA pathophysiology differ from humans. Subcutaneous injection isn't as convenient as oral dosing for chronic conditions. The crossover design is efficient but 4-week washout may be insufficient if liposomal CBD has very long tissue half-life. No comparison to oral CBD in this study. Client-owned dogs continued their routine analgesics, which could mask effects.